M&A

News

Sage rejects Biogen takeover and launches review

Sage Therapeutics has unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company.

R&D

5 takeaways from JP Morgan 2025

I’m back from another week in San Francisco, where as usual I heard from experts and prognosticators about their expectations for the coming year in biotech.

News

Sun Pharma, Taro Pharma, and Antibe Therapeutics logos

Sun Pharma unit poised to buy Canadian biotech Antibe

Sun Pharma's Taro unit has made a bid to acquire Canadian biotech Antibe, a developer of drugs for pain and inflammation.

News

Sage sues Biogen after unsolicited takeover bid

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal.

News

Lilly nets Scorpion cancer drug in $2.5bn licensing deal

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.

News

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

Sage rejects Biogen takeover and launches review

5 takeaways from JP Morgan 2025

Sun Pharma unit poised to buy Canadian biotech Antibe

Sage sues Biogen after unsolicited takeover bid

Lilly nets Scorpion cancer drug in $2.5bn licensing deal

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

Harnessing the cell's own degradation machinery, with Benedi...

How to meet your physicians where they are online

M&A

Editor's Picks